Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Neuroblastoma 1Lymphoma, Large B-Cell, Diffuse 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Cancer Pain 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

resiniferatoxin 1cannabichromene 1Transcutaneous Electric Nerve Stimulation 1Transcranial Direct Current Stimulation 1Tramadol 1Therapeutic Touch 1Telemedicine 1Surveys and Questionnaires 1Standard of Care 1Spinal Cord Stimulation 1Radiosurgery 1Pharmacogenomic Testing 1Patient Education as Topic 1Pain Management 1Oxycodone 1Nerve Growth Factor 1Midazolam 1Massage 1Lidocaine 1Laser Therapy 1Electroacupuncture 1Duloxetine Hydrochloride 1Dronabinol 1Control Groups 1Cognitive Behavioral Therapy 1Cannabidiol 1Art Therapy 1Antibodies 1Acupuncture Therapy 1Acupressure 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cancer Pain × Antibodies × 1 year × Clear all
NCT07008703 2025-06-06

Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain

Shenyang Sunshine Pharmaceutical Co., LTD.

Phase 1/2 Recruiting
132 enrolled

Cancer Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡